{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Commercialization Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Summary Information section of this notice to Fundacao Butantan (Butantan), having a place of business in Sao Paulo, Brazil.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/12/21/2018-27673.html","cfr_references":[],"citation":"83 FR 65697","comment_url":null,"comments_close_on":"2019-01-22","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before January 22, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-27673","effective_on":null,"end_page":65698,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/12/21/2018-27673.xml","html_url":"https://www.federalregister.gov/documents/2018/12/21/2018-27673/prospective-grant-of-exclusive-patent-license-production-of-monovalent-live-attenuated-zika-vaccines","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-27673?publication_date=2018-12-21","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-12-21/2018-27673/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":999,"last_updated":"2026-06-24 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-12-21/pdf/2018-27673.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-27673.pdf?1545313537","publication_date":"2018-12-21","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/12/21/2018-27673.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T23:31:48Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":65697,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Production of Monovalent Live Attenuated Zika Vaccines and Multivalent Live Attenuated Zika and Dengue Vaccines","toc_doc":"Production of Monovalent Live Attenuated Zika Vaccines and Multivalent Live Attenuated Zika and Dengue Vaccines","toc_subject":"Prospective Grant of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}